Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2700 Pancreatic Neuroendocrine Neoplasms and Liver Metastases: When Size Matters

Introduction: Small non-functioning pNENs are low grade indolent tumors, however distant metastases have also been documented in this subset of patients

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Monteleone M, Rossi R, Altomare M, Prinzi N, Cattaneo L,

Keywords: Pancreatic neuroendocrine neoplasia, Liver metastases,

#1914 Prognostic Factors for Long-Term Survival in 102 Consecutive Pancreatic Resections for Primary Neuroendocrine Tumor

Introduction: Neuroendocrine tumors (NET) of the pancreas represent a rare entity of primary pancreatic tumors. However, with the continuous progress in modern diagnostics NET`s are increasingly detected and prognostic factors are being reevaluated to establish personalized treatment concepts.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Klein F, Bahra M, Pratschke J, Pavel M, Pape U,

Keywords: NET, pancreas, surgery,

#1148 Ki67 as a Prognostic Marker in Neuroendocrine Tumours: A Systematic Review of the Literature and Quantitative Synthesis of 5 year Survival Data

Introduction: The ENETS guidelines classify Gastroenteropancreatic Neuroendocrine Tumours (GEP NETs) according to the histological assessment of tumour mitotic count or Ki67 labelling index (LI) on paraffin-embedded tissue, because proliferation rate has been shown to strongly correlate with prognosis. Since the guidelines were published, Ki67 has been established as the more reproducible measure, and further large case series have been reported.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Cave J

Authors: Richards-Taylor S, Tilley C, Hu J, Pearce N, Armstrong T,

Keywords: GEP-NET, prognosis, Ki67,

#1101 Malignant Insulinoma in a Patient with Diabetes: Response to Treatment and a Return to Insulin Injections

Introduction: A 64 year old male with a fourteen year history of diabetes had been treated with insulin for eight years. Over a four week period he noticed that his insulin requirements were reducing and he experienced episodes of symptomatic hypoglycaemia and upper abdominal pain. Following referral a CT scan was performed which revealed numerous liver metastases and a 8.4 by 5.2 cm mass replacing the pancreas. Liver biopsy diagnosed a neuroendocrine tumour with a MIB-1 index of up to 18%. The tumour was somatostatin receptor positive as evidenced by an octreotide scan.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Sherriff D

Authors: Sherriff D, Drake B,

Keywords: insulinoma, diabetes, prrt,

#827 Neuroendocrine Tumors of the Pancreas Grade 2 with Ki-67 Index More Than 5% and with Expression Cytokeratin 19 are the Risk Group of Rapid Progression

Introduction: Cytokeratin 19 (CK19) is the marker of pluripotent cells of the epithelium of the pancreatic ducts, which is not detected in differentiated endocrine cells. Our experience shows that many patients with neuroendocrine tumors of the pancreas (pNET) G2 have a rapid progression of the disease a few years after diagnosis, and metastases are found most commonly in the liver.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Gurevich L, Korsakova N, Kazantseva I, Egorov A, Britvin T,

Keywords: pancreas, neuroendocrine tumors, risk factors, Ki-67, cytokeratin 19,